Ascensia Diabetes Care Announces Commercial Agreement with Dexcom, Inc. to Include CONTOUR®NEXT ONE BGMS with the Dexcom G5® Continuous Glucose Monitoring System for Patients Covered by Medicare

PARSIPPANY, New Jersey, July 10, 2017 /PRNewswire/ --

Ascensia Diabetes Care today announced it has entered into an agreement with DexCom, Inc. ("Dexcom"), the leader in continuous glucose monitoring (CGM) technology, to provide the highly accurate Ascensia CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) as part of the Dexcom G5® CGM System Medicare offering.

The complete bundle will be available to people with diabetes who are covered by Medicare and qualify for therapeutic CGM. Dexcom G5® is currently the only CGM system approved by the FDA to meet the criteria for therapeutic CGM.

Under the terms of the agreement, Ascensia Diabetes Care's CONTOUR^®NEXT ONE BGMS will be provided to eligible people with diabetes in the bundle of supplies for the Dexcom G5® CGM System. The role of the CONTOUR^®NEXT ONE BGMS will be to provide highly accurate readings for CGM calibration.

Michael Kloss, CEO of Ascensia Diabetes Care, explained: "Continuous glucose monitoring is a rapidly growing technology, and Dexcom holds world class expertise in the development and delivery of CGM systems. We are delighted to partner with Dexcom to help this group of patients with their diabetes management, by providing them with our highly accurate CONTOUR®NEXT ONE BGMS as part of the bundle they receive."

Robert Schumm, VP and Managing Director of Ascensia Diabetes Care US Inc., said: "For those people with diabetes who are eligible to receive the G5 through Medicare, Ascensia is thrilled to become the partner of choice for calibration of the Dexcom G5® CGM System. We believe this combination will help improve diabetes management for people on Medicare who are eligible for therapeutic CGM."

The Dexcom G5® CGM System provides dynamic glucose information by showing a user his or her glucose level, along with both trend and rate of change information. People who use the G5® CGM System calibrate regularly to verify the CGM sensor reading is on track.

Rick Doubleday, Chief Commercial Officer, Dexcom, said: "Dexcom is at the forefront of diabetes technology, and in Ascensia, we saw a business partner that matches our own commitment to best-in-class products and services for people with diabetes. With this agreement, we are pleased to begin offering a complete bundle to Medicare-eligible patients, enabling access to the Dexcom G5 CGM System as efficiently as possible."

The Ascensia CONTOUR^®NEXT ONE system when used by itself has been shown to deliver remarkable accuracy, with 95% of results within ±8.4 mg/dL or ±8.4% of the laboratory reference values for glucose concentrations < 100 mg/dL or ≥ 100 mg/dL, respectively in the hands of patients.^[1]

Notes for Editors 

About Ascensia Diabetes Care 

Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.

Home to the world renowned CONTOUR^® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 33 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com

© 2017 Ascensia Diabetes Care. Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

For further information, please contact: Joseph Delahunty, Ascensia Diabetes Care, [email protected], Tel: +41-61-560-8760

1. Christiansen et al. Poster presented at the 15th Annual Meeting of the Diabetes Technology Society, October 22-24, 2015, Bethesda, Maryland.

SOURCE Ascensia Diabetes Care